Evolus (EOLS)

Executive Summary

Evolus, Inc. (NASDAQ: EOLS) is a commercial-stage biotechnology company focused on medical aesthetics. Its lead product, Jeuveau (prabotulinumtoxinA), is approved for temporary improvement of moderate to severe glabellar lines in adults. The company maintains a pipeline of 10 drug candidates, including studies for rhytides, skin aging, and neck muscle issues. Recent clinical activity includes a Phase 2 glabellar lines study (expected completion Jan 2026) and a recruiting study for neck muscle issues (completion Mar 2026). Evolus leverages its proprietary botulinum toxin formulation to compete in the growing aesthetics market, targeting both U.S. and international expansion. With a strong commercial foundation and ongoing R&D, the company is positioned for near-term growth as it advances pipeline candidates and seeks to broaden its label.

Upcoming Catalysts (preview)

• Q2 2026Top-line data from neck muscle (platysma) Phase 2 study (NCT06903975)80% success
• H2 2026FDA submission or pre-NDA meeting for new aesthetic indication (e.g., neck muscle)60% success
• Q3 2026Quarterly earnings with guidance update and commercial traction90% success